Antimicrobial

Fortifeye Vitamins Unveils the Cutting-Edge, Next Gen, Zinc-Free Macular Defense Formula, Elevating Eye Health to New Heights

Fortifeye Vitamins Releases Next Gen, Zinc-Free Macular DefenseOCALA, FL / ACCESSWIRE / July 28, 2023 / Fortifeye Vitamins, a pioneering…

1 year ago

T2 Biosystems to Attend Upcoming Investor Conferences

LEXINGTON, Mass., July 28, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens…

1 year ago

CorMedix Inc. to Report Second Quarter 2023 Financial Results and Provide a Corporate Update on August 8, 2023

BERKELEY HEIGHTS, N.J., July 26, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and…

1 year ago

Pressure BioSciences Launches Program to Evaluate Company’s Patented UltraShear Process in Breakthrough Application to Extend Shelf-Life of Fresh Produce

Scientific Publications Demonstrate Effectiveness of CBD and Essential Oil Nanoemulsions in Shelf-Life Extension of Fruits and Vegetables; PBI Initiating Studies…

1 year ago

Fortifeye Vitamins Breaks New Ground With Next Gen Zinc-Free Macular Degeneration Formula

Fortifeye Vitamins Introduces Next Gen Zinc-Free Macular DefenseOCALA, FL / ACCESSWIRE / July 25, 2023 / Fortifeye Vitamins, a leading…

1 year ago

AUROBAC THERAPEUTICS welcomes two new independent members to its Board: Manos Perros, as Chairman, and Marco Taglietti

These new appointments bring extensive US and international experience in company leadership and development of anti-infectives from R&D to commercialization.Lyon…

1 year ago

T2 Biosystems Announces Preliminary Second Quarter 2023 Financial Results

Received record quarterly sepsis test panel orders and strengthened balance sheetLEXINGTON, Mass., July 12, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems,…

1 year ago

Aridis’ AR-301 Monoclonal Antibody is Among the First Biologics to Receive FDA’s Qualified Infectious Diseases Product (QIDP) Designation

QIDP designation for Biologics provides FDA Priority Review statusLOS GATOS, Calif., July 12, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc.…

1 year ago

Recce Pharmaceuticals Announces First Cohort Dosed in RECCE® 327 Rapid Infusion Phase I/II Urinary Tract Infection (UTI) Clinical Trial

Highlights: First cohort in Phase I/II urinary tract infection (UTI) rapid infusion intravenous (IV) study successfully dosed 2,500mg of RECCE®…

1 year ago

Oxford University scientists’ AI diagnostic test accurately identifies known respiratory viruses in minutes

Breakthrough in diagnostics testing enables ‘facial recognition for germs’ Collaboration with John Radcliffe Hospital used AI to identify respiratory viruses…

1 year ago